Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:23:50.999Z.
Calculation as of: 2026-10-06T22:23:50.999Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 91899883c476d55b2433093e583c87952940339a9b77bc55d8a3dd78c9ec7759
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$973.93M
Price/OCF Ratio
5.19
TTM Avg
6.80
3Y Avg
7.11
5Y Avg
11.19
Market Cap
$929.83M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.09M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Price/OCF Ratio
71.71
TTM Avg
103.87
3Y Avg
103.87
5Y Avg
103.87
Market Cap
$982.46M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $952.91M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | N/A | 6.63 | 6.62 | 6.62 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 5.19 | 6.80 | 7.11 | 11.19 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 71.71 | 103.87 | 103.87 | 103.87 |
| CeriBell, Inc. (CBLL)vs › | $923.53M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
